Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4

Open access

Abstract

Dysregulation of cyclin-dependent kinase 4 (CDK4) and CDK6 by gain of function or loss of inhibition is common in human cancer, including multiple myeloma, but success in targeting CDK with broad-spectrum inhibitors has been modest. By selective and reversible inhibition of CDK4/CDK6, we have developed a strategy to both inhibit proliferation and enhance cytotoxic killing of cancer cells. We show that induction of prolonged early-G(1) arrest (pG1) by CDK4/CDK6 inhibition halts gene expression in early-G(1) and prevents expression of genes programmed for other cell-cycle phases. Removal of the early-G(1) block leads to S-phase synchronization (pG1-S) but fails to completely restore scheduled gene expression. Consequently, the IRF4 protein required to protect myeloma cells from apoptosis is markedly reduced in pG1 and further in pG1-S in response to cytotoxic agents, such as the proteasome inhibitor bortezomib. The coordinated loss of IRF4 and gain of Bim sensitize myeloma tumor cells to bortezomib-induced apoptosis in pG1 in the absence of Noxa and more profoundly in pG1-S in cooperation with Noxa in vitro. Induction of pG1 and pG1-S by reversible CDK4/CDK6 inhibition further augments tumor-specific bortezomib killing in myeloma xenografts. Reversible inhibition of CDK4/CDK6 in sequential combination therapy thus represents a novel mechanism-based cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-03-415984

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 110

Metadata

Authors
Huang, X., Di Liberto, M., Jayabalan, D., Liang, J., Ely, S., Bretz, J., Shaffer, A. L., Louie, T., Chen, I., Randolph, S., Hahn, W. C., Staudt, L. M., Niesvizky, R., Moore, M. A. S., & Chen-Kiang, S.
Affiliations
  • Departments of Pathology and Laboratory Medicine and
  • Weill Cornell Medicine (US)
  • National Institutes of Health (US)
  • Pfizer (United States) (US)
  • Broad Institute (US)
  • Medicine, and
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Huang, Xiangao
Venue
Blood
Published
2012-08-02
Volume
120
Issue
5
Pages
1095-1106
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2041694372
Cited by
102
References
48
Citations by year
2026: 5 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 12 · 2021: 11 · 2020: 11 · 2019: 6 · 2018: 5 · 2017: 5 · 2016: 8 · 2015: 11 · 2014: 6 · 2013: 7 · 2012: 3
FWCI
5.75
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • National Institutes of Health
  • U.S. Public Health Service (R01 120531)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
multiple myeloma, IRF4, bortezomib, apoptosis, building information modeling, Noxa, S phase synchronization, proteasome inhibitors, combination therapy, cell cycle regulation
MeSH terms
Bortezomib, Interferon Regulatory Factor-4, Animals, Boronic Acids, Cell Cycle, Cytotoxins, Drug Synergism, Humans, Mice, Transgenic, Multiple Myeloma, Pyrazines, Substrate Specificity, Time Factors, Down-Regulation, Gene Expression Regulation, Neoplastic, Mice, SCID, Mice, Inbred NOD, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Interferon Regulatory Factors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, G1 Phase Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4. https://app.cochat.ai/papers/10.1182/blood-2012-03-415984
The paper
Huang, X., Di Liberto, M., Jayabalan, D., Liang, J., Ely, S., Bretz, J., Shaffer, A. L., Louie, T., Chen, I., Randolph, S., Hahn, W. C., Staudt, L. M., Niesvizky, R., Moore, M. A. S., & Chen-Kiang, S. (2012). Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4. Blood. https://doi.org/10.1182/blood-2012-03-415984

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.